These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 19243718)

  • 1. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
    Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
    Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
    J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
    Kotirum S; Chongmelaxme B; Chaiyakunapruk N
    J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Burness CB; McKeage K
    Drugs; 2012 May; 72(7):963-86. PubMed ID: 22564134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
    Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
    Eriksson BI; Friedman RJ
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review.
    Brockbank J; Wolowacz S
    Pharmacoeconomics; 2017 May; 35(5):517-535. PubMed ID: 28185212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.